MeSH D016410 - t-cell lymphoma cutaneous
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Amneal Pharmaceuticals | Bexarotene | Bexarotene |  | 2018-09-04 |  |  |
| Romidepsin | Romidepsin |  | 2026-06-02 |  |  | |
| ANI Pharmaceuticals | Bexarotene | Bexarotene |  | 2018-05-08 |  |  |
| Ascent Pharmaceuticals | Bexarotene | Bexarotene |  | 2024-09-06 |  |  |
| Bausch Health Companies | Bexarotene | Targretin |  | 1999-12-29 |  |  |
| BionPharma | Bexarotene | Bexarotene |  | 2014-08-12 |  |  |
| Bristol Myers Squibb | Romidepsin | Istodax |  | 2009-11-05 |  |  |
| Cipla | Bexarotene | Bexarotene |  | 2024-12-10 |  |  |
| Eisai | Bexarotene | Targretin |  | 2001-03-29 |  |  |
| Fresenius Kabi | Romidepsin | Romidepsin |  | 2021-10-12 |  |  |
| Hikma Pharmaceuticals | Bexarotene | Bexarotene |  | 2020-06-16 |  |  |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
50%18/36
Phase 2
16%7/44
Phase 3
69%9/13
Approved: 4Overall Success rate: 6%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use